menu Search
Sybrava

Sybrava

inclisiran

Manufacturer:

Novartis Pharmaceutical Manufacturing GmbH

Distributor:

Novartis Healthcare
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Inclisiran
Indications/Uses
Primary hypercholesterolemia (heterozygous familial & non-familial) or mixed dyslipidemia in adults, as adjunct to diet in combination w/ statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ max tolerated statin dose; or alone or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant or for whom statin is contraindicated.
Click to view Sybrava detailed prescribing information
Dosage/Direction for Use
SC Initially 284 mg as single SC inj into abdomen. Repeat at 3 mth, followed by every 6 mth.
Click to view Sybrava detailed prescribing information
Overdosage
View Sybrava overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity.
Click to view Sybrava detailed prescribing information
Special Precautions
Not to be given into areas of active skin disease or injury eg, sunburns, skin rashes, inflammation or infections. If administering to patients on hemodialysis, do not perform hemodialysis for at least 72 hr after treatment. Have not been studied in patients w/ severe hepatic impairment (Child-Pugh class C). Pregnancy & lactation. Safety & efficacy have not been established in ped patients <18 yr.
Click to view Sybrava detailed prescribing information
Use In Pregnancy & Lactation
Click to view Sybrava detailed prescribing information
Adverse Reactions
Inj site reactions eg, pain, erythema, rash.
Click to view Sybrava detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Sybrava detailed prescribing information
Storage
View Sybrava storage conditions for details to ensure optimal shelf-life.
Description
View Sybrava description for details of the chemical structure and excipients (inactive components).
Action
View Sybrava mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX16 - inclisiran ; Belongs to the class of other lipid modifying agents.
Regulatory Classification
Rx
Presentation/Packing
Form
Sybrava soln for inj 284 mg/1.5 mL
Packing/Price
1's